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About 200 coactivators play a central role in promoting gene expression mediated by 
nuclear receptors. This diverse group of proteins are key integrators of signals from steroid 
hormones and have been implicated in cancer and other diseases.Introduction
Nuclear receptors (NRs) comprise a 
superfamily of conserved transcrip-
tion factors that are activated by their 
steroid hormone ligands and play 
essential roles in diverse biological 
processes. For example, the estro-
gen, progesterone, and androgen 
receptors are important in reproduc-
tion; glucocorticoid receptors in glu-
cose metabolism and stress; the thy-
roid hormone receptor in oxidative 
metabolism; and PPARs in lipid and 
energy metabolism (Mangelsdorf et 
al., 1995). Coactivators are molecules 
recruited by ligand bound activated 
NRs (or other DNA binding transcrip-
tion factors) that elicit enhanced 
gene expression. In contrast to NRs, 
which are structurally conserved, 
their coactivators are diverse, both 
structurally and in the way they con-
tribute to the transcriptional process, 
namely through a diverse array of 
enzymatic activities such as acety-
lation, methylation, ubiquitination, 
and phosphorylation or as chroma-
tin remodelers. NR coactivators are 
essential effectors of the biological 
activities of NRs and their ligands 
(Xu et al., 1999). Although the focus 
of this essay is NR coactivators, con-
ceptually they work in a manner simi-
lar to general coactivators for other 
transcription factors.
There is little doubt that the coun-
terparts of coactivators, corepres-
sors, are equally important to the 
cell (Glass and Rosenfeld, 2000). 
Corepressors interact with NRs 
that are not bound to ligand and 
repress transcription. Corepressor-associated proteins such as histone 
deacetylases enforce a local chro-
matin environment that opposes the 
transcription-promoting activities of 
coactivators (such as histone acetyl-
transferase). Through their opposing 
actions, a balance exists between 
coactivators and corepressors that 
defines the magnitude and nature of 
responses to NR ligands.
Coactivators and Transcriptional 
Regulation
Initial experiments in yeast pro-
duced a picture of coactivators as 
“transcriptional adaptors” (Ptashne 
and Gann, 1990). These adaptors 
were predicted to provide a bridge 
between DNA binding transcription 
factors and the general transcription 
machinery. This simple scenario of 
coactivator action turned out to be 
much more complex.
Coactivators are predicted to have 
many activities in addition to the 
initiation of transcription, such as 
mRNA transport from the nucleus, 
mRNA translation, and posttransla-
tional modifications of the synthe-
sized protein. That coactivators pos-
sess stratified actions in the entire 
process of transcription/translation 
reflects the fact that they do not act 
alone but rather as part of multipro-
tein complexes. These multisubunit 
entities, containing many individual 
enzymatic activities, represent a 
complex machine that is able to con-
centrate and link diverse enzymes, 
and the processes that they regulate, 
together in one place. In this way, the 
coactivator complex executes the Cell 12coactivator’s final agenda—that is, to 
see a particular gene expressed as a 
mature functional protein.
After identification of the first 
NR coactivator—the steroid recep-
tor coactivator SRC-1 (Onate et al., 
1995)—it was predicted that there 
might be a small family of coactiva-
tors (perhaps five to ten) that carried 
out the bridging role between tran-
scription factor and transcriptional 
machinery. There are now ?200 pub-
lished NR coactivators that work with 
?48 NRs. Of these, ?50–70 have 
been characterized by more than 
one laboratory and have been defini-
tively shown to be NR coactivators. 
Clearly, we are far from identifying 
the totality of authentic NR coactiva-
tors (http://www.nursa.org) or their 
specific functions in the cell.
Transcription is a highly dynamic 
and orderly process involving many 
subreactions (multiple steps of ini-
tiation, elongation, splicing, and ter-
mination). Given that so many NR 
coactivators have been identified, 
there is certainly no shortage of them 
to participate in the wide variety of 
transcription subreactions. But why 
would a cell possess such a cumber-
some transcriptional apparatus? The 
answer may lie in the fact that mam-
mals are substantially more complex 
than organisms such as yeast, worm, 
and the fruit fly, which have far fewer 
NR coactivators. For instance, only 
a single NR coactivator (Taiman/
dAIB1) has been identified in fruit 
flies so far.
Coactivator activity results in par-
ticular physiological consequences. 5, May 5, 2006 ©2006 Elsevier Inc. 411
For instance, the 
PGC-1 coactivator is 
expressed when an 
organism needs to 
alter its metabolic pro-
gram in response to 
exercise or cold tem-
peratures (Lin et al., 
2005). Work in mice 
lacking the coactiva-
tors SRC-1 and SRC-
2 reveals their impor-
tance in carbohydrate 
and lipid metabolism 
(Picard et al., 2002). 
Thus, although at first 
glance they appear to 
act only in transcrip-
tional control, coacti-
vators are impor-
tant for modulating 
the expression of a 
wide array of physi-
ologically important 
groups of genes.
A Cacophony of 
Activities
For transcription to 
proceed, there need to 
be histone modifica-
tions (such as acetyla-
tion and methylation), 
ATPase-dependent 
chromatin remodeling, 
initiation of transcrip-
tion, elongation, alter-
native RNA splicing 
and mRNA process-
ing, and termination. 
The focus of coactiva-
tor enzymatic activi-
ties in these processes 
has centered on the posttranslational 
modification of histones and chroma-
tin. However, it is becoming clear 
that NRs and their coactivators are 
also subject to posttranslational 
modification. For instance, ligand-
dependent sumoylation of PPARγ 
mediates the repression of inflam-
matory response genes (Pascual 
et al., 2005). The posttranslational 
targeting of NRs and their coacti-
vators is important because these 
modifications influence the expres-
sion of functionally related groups 
of genes.
For cessation of transcription, RNA 
polymerase must dissociate from the 
gene and reinitiation of transcrip-
tion must be curtailed. As part of the 
cessation of transcription, coactiva-
tors and their NRs are modified by 
ubiquitination and degraded by the 
proteasome. In addition to transcrip-
tional termination, the ubiquitin pro-
teasome degradation system is likely 
to be important in clearing “used” 
coactivator complexes from the pro-
moter, allowing for subsequent steps 
in sequential transcription to ensue. 
Here, the ubiquitin proteasome 
degradation system 
plays a positive role 
in transcription prior 
to a subsequent duty 
in transcription ter-
mination (Reid et al., 
2003). This theory 
may account for 
the large number of 
coactivators that are 
E2 and E3 ligases, 
such as E6-AP, RPF-
1, UbcH7, and p300. 
One can envisage 
the recruitment of a 
procession of coacti-
vators—for example, 
during transcription 
initiation, there would 
be SRCs and p68; 
chromatin remodel-
ers such as BRG-1 
and other ATPase-
dependent chroma-
tin remodelers; and 
histone modifiers 
(histone acetyltrans-
ferases and methyl-
transferases) such 
as p300/CBP, SRCs, 
and CARM-1. Later 
during transcription, 
elongation would be 
mediated by P-TEFb 
followed by alterna-
tive splicing of mRNA 
by PGC-1, CAPER, 
and CoAA. Finally, 
transcriptional-com-
plex remodeling or 
the termination of its 
activities would be 
accomplished by E6-
AP, SSA, and TRIP1 (Metivier et al., 
2006). There is no doubt that newly 
identified coactivators will continue 
to be a prime source for the discov-
ery of new molecular events in tran-
scriptional reactions.
Coactivators: Integrators of the 
Cellular State
Primary or core coactivators—those 
that interact directly with NRs—exist 
in steady-state complexes with sec-
ondary or co-coactivator partners 
(Stallcup et al., 2003) (see Figure 
1). The coactivator core complex is 
Figure 1. Coactivator-Directed Gene Expression
(Left panel) Activation of a nuclear receptor (NR) by binding of its steroid-hormone 
ligand results in activation of kinase A, which induces a distinct phosphorylation 
pattern (P) in a core coactivator (Core CoA). Protein remodelers (Pin1, Hsps, pro-
teasome ATPases) direct the incorporation of a unique set of co-coactivators (Co 
Co; examples include p300 and the ubiquitin-conjugating ligases UbC and UbL) 
into a distinct multiprotein coactivator complex. The composition of this com-
plex favors enhancement of NR-mediated transcription of target genes. Various 
enzymatic activities assigned to these co-coactivators (acetylation, Ac; methyla-
tion, Me) can target protein members of neighboring complexes. This results in 
dissociation of members of these complexes, followed by their destruction by 
UbC and UbL. 
(Right panel) Signaling through membrane receptors via kinase B induces a phos-
phorylation pattern distinct from that of Core CoA. This pattern results in the in-
tegration of alternative co-coactivators (Co Co), leading to a complex that favors 
transcription mediated by non-NR transcription factors (TF). After their transcrip-
tional roles are complete, the complexes are ubiquitinated and degraded by the 
proteasome.412 Cell 125, May 5, 2006 ©2006 Elsevier Inc.
composed of a tightly bound invari-
ant group of proteins, whereas the 
more loosely bound co-coactivators 
associate with the core complex in 
a dynamic, regulated manner. Per-
haps a higher-order “complex of 
complexes” also forms, enabling 
coactivator intercomplex commu-
nication and efficient integration of 
signaling pathways such as those 
required for metabolism, growth, 
and inflammation. The fact that 
coactivators belong to distinct com-
plexes may explain how more than 
200 different coactivator proteins 
individually contribute to cell regula-
tion in a coherent manner.
Because coactivators exist as mul-
tiprotein complexes, a member of a 
single coactivator complex can serve 
as a rate-limiting conduit to control 
the actions of the whole complex. 
For example, the phosphorylation 
status of SRC-3 defines its associa-
tion with other members of the com-
plex, such as p300 and CBP histone 
acetyltransferase or CARM1 meth-
yltransferase (Wu et al., 2005). This 
attendant signaling feature afforded 
by coactivator complexes suggests 
that coactivators may be integrators 
of multiple cell signaling systems. 
Activation of membrane receptors 
and signaling cascades may allow 
the genome to sense the impact of 
the total environment on the cell. 
Given that coactivators can organize 
the expression of “functional groups” 
of genes involved in the execution of 
a specific regulatory regime (such 
as genes involved in metabolism, 
growth, or cytokine action), they are 
prime targets for posttranslational 
modification and modulation by 
kinase cascades (Wu et al., 2005). 
Phosphorylation of coactivators by 
kinases, such as IKKα and CDK2, 
modulates NR-mediated transcrip-
tion by altering the affinity between 
different coactivators and their NRs, 
influencing which transcription fac-
tors they are able to coactivate (Wu 
et al., 2005; Narayanan et al., 2005). 
Other modifications, such as methyl-
ation or acetylation, can promote the 
dynamic dissociation of coactiva-
tor-complex components (Xu et al., 
2003; Lee et al., 2005). In the end, final occupation of binding sites on 
protein partners is a product of both 
their cellular concentration and their 
affinity for each other. In the case of 
SRC-3, phosphorylation of a spe-
cific combination of residues defines 
which transcription factors this coact-
ivator is able to activate, suggesting 
that there may be a “phosphorylation 
code” (Wu et al., 2005). The selec-
tively phosphorylated coactivator 
can be conscripted to preferentially 
implement the expression of genes 
downstream of a particular growth-
factor signaling cascade. Binding of 
coactivators to NRs generally occurs 
through LXXLL interaction motifs in 
the coactivator. Many coactivators 
possess several different receptor-
interacting LXXLL motifs, enabling 
them to bind to different combina-
tions of NRs. Complexity is also 
afforded through these LXXLL motifs 
by amino acid residues that flank 
these sequences. In some cases, 
these flanking residues are also sub-
ject to posttranslational modifica-
tions, allowing for the dynamic con-
trol of this NR-interacting motif.
Histone Modification: Directed 
versus Distributed Regulation
Coactivator-mediated histone modi-
fications play an important role in 
regulating the transcription of a par-
ticular gene, but the biological impact 
is limited usually to that target gene. 
Coactivators, however, can direct 
their enzymatic action toward other 
coactivator proteins (Xu et al., 2003; 
Lee et al., 2005). Conceptually, cross-
posttranslational modification of one 
coactivator by another would allow the 
affected coactivator (and the coacti-
vator complex that it resides in) to 
act in an altered manner on a “global 
scale” similar to the far-reaching bio-
logical effects that kinases exert on 
SRC-3 function. Although the histone 
modification code may define the tran-
scriptional state of individual genes, 
coactivator modification codes (acety-
lation, methylation, phosphorylation) 
may define the transcriptional state of 
broad groups of functionally related 
genes and may control coactivator 
preferences among NRs and other 
transcription factors (see Figure 1).Cell 12Transcriptional Dynamics: 
Remodeling, Removal, Reinitiation
That many coactivators contribute 
to NR-dependent gene expres-
sion suggests the presence of a 
dynamic force that acts as a pro-
pulsion system for these transcrip-
tional machines. In a simple system 
involving only a few proteins, thermal 
Brownian-driven association and 
dissociation would be sufficient to 
allow for the necessary proteins to 
associate, perform their enzymatic 
roles, and dissociate, allowing other 
proteins to then be recruited to do 
their jobs. Although Brownian forces 
are likely to play some role, such a 
simple physical force is unlikely to be 
sufficient for transcription to ensue. 
An orderly procession of coactiva-
tor proteins must associate with the 
promoter for efficient transcription 
(An et al., 2004). Many other pro-
teins interact with the promoter in an 
orderly sequential fashion (Reid et 
al., 2003), such that additional orga-
nizing processes must be involved to 
actively disrupt and rearrange these 
coactivators.
So what are some of the motive 
forces that allow for orderly remod-
eling capabilities? Protein degrada-
tion via the proteasome is one force 
that makes this procession possible. 
Because protein degradation medi-
ated by the ubiquitin-proteasome 
system is a highly regulated and spe-
cific process, it is capable of selec-
tively removing coactivator proteins 
after they have fulfilled their roles in 
transcription, clearing the way for 
subsequent coactivator associations 
with the promoter. The ubiquitin-pro-
teasome system is itself remarkably 
complex, as evidenced by the large 
number of ubiquitin ligases responsi-
ble for the directed targeting of ubiq-
uitin to proteasome substrates, mak-
ing it the largest class of enzymes 
in mammalian cells. Another group 
of proteins that may play essential 
roles in coactivator dynamics are 
the ATP-driven protein chaperones. 
An example of a protein that alters 
coactivator protein conformation is 
Pin1, a prolyl isomerase that cata-
lyzes the cis-trans isomerization of 
proline residues in SRC-3 (see Fig-5, May 5, 2006 ©2006 Elsevier Inc. 413
ure 1). Such a transition in a proline 
residue is capable of evoking a large 
steric change in the protein and can 
serve as an additional mechanism 
to dynamically alter coactivator pro-
tein conformation during complex 
assembly.
RNA Coactivator Complexes
SRA is a unique NR coactivator in 
that it is an RNA (Lanz et al., 1999). 
Although a paucity of data exists, 
we believe that there will be other 
RNAs that turn out to be NR coacti-
vators. As for SRA itself, it may play 
a structural role as it is subject to 
a posttranscriptional modification 
by pseudouridine synthase (which 
converts uracil to pseudouracil) that 
alters its conformation (Zhao et al., 
2004). RNAs may be an important 
structural molecule in coactivator 
complexes, playing a part similar to 
that of structural RNAs in ribosomes. 
A number of splicing-related coacti-
vators such as p68, p72, CAPER, and 
PGC-1 possess RNA binding motifs; 
their uncharacterized RNA binding 
partners may represent other RNA 
coactivators. SRA is also a part-
ner in complexes with the SHARP 
and SLIRP corepressor proteins, 
suggesting a broader role for RNA 
molecules as both coactivators and 
corepressors.
Conclusion
If coactivators are key regulators of 
transcription, what regulates their 
expression? Most coactivators appear 
to be regulated either by posttrans-
lational mechanisms that determine 
their stability or by control of their 
activity through phosphorylation, 
although a few, including PGC-1, are 
regulated through increased tran-
scription of the parent gene. If regu-
lation of coactivators occurred only 414 Cell 125, May 5, 2006 ©2006 Elseviethrough transcription of their parent 
genes, then those genes also would 
require their own set of regulatory 
coactivators and so on, resulting in 
a never-ending circle of regulatory 
molecules.
Coactivators play important roles in 
diverse pathological processes, such 
as cancer, inherited genetic diseases, 
metabolic disorders, and inflam-
mation. The cancer cell, dedicated 
to relentless growth, is certainly a 
master at accumulating high levels of 
“growth coactivators” such as SRC-
3/AIB1, thereby assuring a preferen-
tial rate of expansion (Anzick et al., 
1997). Germline mutations affecting 
E6-AP result in the inherited genetic 
disease Angelman syndrome, (Mat-
suura et al., 1997). Polymorphisms 
in PGC-1 may lead to increased sus-
ceptibility to type II diabetes (Lin et 
al., 2005). Finally, variations in the 
expression of coactivators among dif-
ferent individuals may be associated 
with phenotypic differences among 
humans. There is little doubt that we 
have much to learn about the biologi-
cally diverse roles of NR coactivators 
and that we have only scratched the 
surface of this expansive coactivator 
cosmos.
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